Cabergoline

Inhibition/suppression of physiological lactation Cabergoline is indicated for the inhibition of physiological lactation soon after delivery and for suppression of already established lactation: 1. After parturition, when the mother elects not to breast feed the infant or when breast feeding is contraindicated due to medical reasons related to the mother or the new-born.

2. After stillbirth or abortion. Cabergoline prevents/suppresses physiological lactation by inhibiting prolactin secretion. In controlled clinical trials, cabergoline given as a single 1 mg administration during the first day post-partum, was effective in inhibiting milk secretion, as well as breast engorgement and pain in 70 - 90% of the women.

Less than 5% of women experienced rebound breast symptomatology during the third post-partum week (which was usually mild in severity). Suppression of milk secretion and relief of breast engorgement and pain are obtained in approximately 85% of nursing women treated with a total dose of 1 mg cabergoline given in four divided doses over two days.

5 mg Leucine USP and Lactose anhydrous For a complete listing see Dosage Forms, Composition and Packaging section.

INDICATIONS AND CLINICAL USE DOSTINEX* is indicated for:

Treatment of hyperprolactinemic disorders: DOSTINEX (cabergoline) is indicated for the treatment of hyperprolactinemic disorders, either idiopathic or due to pituitary adenomas.

Inhibition of physiological lactation:

DOSTINEX (cabergoline) is indicated for the prevention of the onset of physiological lactation in the puerperium for clearly defined medical reasons. These medical reasons may include birth of a still born baby, neonatal death, conditions interfering with suckling (cleft lip or palate of the baby), severe acute or chronic mental illness or medical conditions, maternal disease which may be transmitted to the baby that require medications which are excreted in the milk.